[1] Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, et all. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1?2 study. Lancet Oncol. 2017 Jun; 20 (6). DOI: http://dx.doi.org/10.1016/S1470-2045(17)30416-3.
[2] Perl AE, Altman JK, Cortes JE, Smith CC, Litzow M, Baer MR, Claxton DF, Erba HP, et all. Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Acute Myeloid Leukemia: Novel Therapy. Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: FLT3 and IDH Targeted Therapies in AML. American Society of Hematology (ASH)/ Monday, December 5, 2016 | San Diego.
[3] Adult Acute Myeloid Leukemia Treatment (PDQ?)?Health Professional Version. General Information About Adult Acute Myeloid Leukemia (AML). Online. National Cancer Institute. https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq. Last accessed June 22, 2017.
[4] Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical Trial. NCT02014558
Home Perl AE, Altman JK
